Rahul Banerjee: All I care about in myeloma is VGPR report
Rahul Banerjee, Assistant Professor at UW Medicine, shared Rafael Fonseca’s post on X, adding: .
“This! All I care about in myeloma is ≥VGPR vs <VGPR in terms of determining next steps diagnostically and therapeutically.
Next step is MRD (Minimal Residual Disease) assessment, not a 24-hour urine to confirm <100mg in unless they’re on trial in which it’s inevitable for the time being.”
Quoting Rafael Fonseca’s post:
“Reporting in trials response categories (PR vs VGPR vs CR vs sCR) and later showing MRD seems a wasteful redundancy.
Is like rounding and spending time discussing a plain chest X-ray, only to move on and discuss the chest CT.”
Source: Rahul Banerjee/X and Rafael Fonseca/X
Dr. Rafael Fonseca, M.D., is a hematologist at Mayo Clinic, specializing in multiple myeloma and related conditions.. Dr. Fonseca’s expertise extends to diagnosing and treating plasma cell disorders, leading clinical trials that have advanced myeloma treatment.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023